Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pain
- Sponsor
- National Cheng Kung University
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Pain, assessed by BPI-SF.
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Pain is one of the most common symptoms associated with cancer. The approach to pain management compresses routine pain assessments, utilizes both pharmacologic and nonpharmacologic interventions, and requires ongoing reevaluation of the patient. Cancer pain can be well controlled in the vast majority of patients if the algorithms of pain control are systematically applied, carefully monitored, and tailored to the needs of the individual patient.This study is aimed to assess the current pain managements in upper gastrointestinal cancer patients in Taiwan. The effects of neuropathic pain and depression on the enrolled patients would also be assessed.
Investigators
Hsu-chih Chien
Doctoral student
National Cheng Kung University
Eligibility Criteria
Inclusion Criteria
- •with a diagnose of advanced upper GI cancer based on pathology or imaging studies
- •could report pain intensities and answer questionnaires by him/herself
Exclusion Criteria
- •with major neurologic or psychiatric diseases
- •could not report pain intensities and answer questionnaires by him/herself
Outcomes
Primary Outcomes
Pain, assessed by BPI-SF.
Time Frame: Assessed at enrolled date (Day 1)
Pain intensities of participants would be assessed by BPI-SF at D1.
Changes in pain, assessed by BPI-SF.
Time Frame: Baseline and 1 month.
Changes in pain intensities of participants would be assessed by BPI-SF. The changes in pain would be assessed again after 1 month when participants have outpatient visits or during their admission. An expected following duration average of would be 4 weeks.
Secondary Outcomes
- Depression, assessed by two stem questions.(Assessed at enrolled date (Day 1))
- Changes in depression, assessed by two stem questions.(Baseline and 1 month.)
- Quality of life, assessed by EROTC QLQ C30.(Day 1)
- Neuropathic pain, assessed by DN4 questions.(Day 1)
- Changes in quality of life. Quality of life, assessed by EROTC QLQ C30.(Baseline and 1 month.)
- Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions.(Baseline and 1 month.)